Interpersonal Functioning & Social Connectedness
Few claims about psychedelics are as appealing as the social one: that they make people feel more connected, more empathic, more at ease with others. This page examines what the evidence actually supports. The firmest finding is that MDMA acutely increases empathy, trust and warmth, an effect specific enough to separate it from a plain stimulant and linked to the hormone oxytocin. Classic psychedelics raise emotional empathy too, though not social understanding. But "connectedness" has also become a catch-all, a single fuzzy idea stretched to explain everything these drugs do, and the evidence for durable change in real relationships is thin. Most of it is acute, self-reported, and gathered in healthy volunteers. This is a real and interesting domain of effect, and one where the warm language runs well ahead of the hard outcomes.
Data updated
Key Insights
- 1
This is a theme page about a domain of effect and a proposed mechanism, not a condition or a treatment. The question is how psychedelics change social and interpersonal experience: empathy, trust, warmth, loneliness, and the sense of being connected to others.
- 2
The best-evidenced effect is MDMA’s acute prosociality. It reliably raises empathy, trust and closeness, the effect is specific enough to distinguish it from a stimulant like methamphetamine, and it tracks the release of oxytocin. This is the clearest social signal in the whole field.
- 3
Classic psychedelics raise emotional empathy (warmth, feeling-with) but not cognitive empathy (accurately reading others). The prosocial effect is affective, not an improvement in social skill or understanding, a distinction the enthusiastic language often blurs.
- 4
"Connectedness" has become a popular but slippery idea. It is measured by self-report scales in the same people who report feeling better, which makes mechanism and outcome hard to separate, and the construct has been stretched so far (one paper rebrands MDMA a "connectogen") that it risks explaining everything and therefore nothing.
- 5
The crucial caveat is that almost all the strong evidence is acute, self-reported, and from healthy volunteers in small samples. Feeling warm and connected ninety minutes after a dose is not the same as lasting change in real relationships, and durable, behaviourally measured interpersonal benefit is largely unproven.
By the numbers
- 34
- Trials tracked
- 178
- Papers tracked
- 1,314
- Trial participants
as of June 2026
as of June 2026
as of June 2026
About Interpersonal Functioning & Social Connectedness
Interpersonal functioning and social connectedness is not a condition or a treatment; it is a domain of effect that cuts across the whole field. Psychedelics are famous for changing how people feel about other people, more empathic, more trusting, more connected, and that social shift is both one of their most reported effects and one of the most popular explanations for why they might help. This page looks at what the research actually shows about those effects, and at how much weight the increasingly fashionable idea of "connectedness" can really bear.
There is a genuine, well-evidenced core here. MDMA in particular produces a reliable acute increase in empathy, trust and social warmth, and the effect is specific enough that it can be separated from the effect of a plain stimulant. Classic psychedelics, too, acutely raise emotional empathy. These are real pharmacological phenomena, studied carefully, and they are the legitimate heart of the topic. Some of this work overlaps with specific conditions, such as social anxiety in autistic adults, which is covered on its own page.
Around that core, though, the language tends to inflate. "Connectedness" has grown from a specific, measurable feeling into a catch-all that is asked to explain depression relief, addiction recovery, spiritual experience and relationship repair all at once. The single most important idea to carry through this page is the gap between an acute feeling and a durable change: a warm, connected state under a drug is a real effect, but it is not, by itself, evidence that someone’s relationships or social life are lastingly better. Holding that distinction is what separates the honest version of this topic from the hopeful one.
Approach & Methods
Because there is no condition here, the relevant "standard practice" is how the social effects are studied, and the best of that work is unusually rigorous. The strongest design compares MDMA against a stimulant comparator, so that "feeling good and talkative" cannot be mistaken for genuine prosociality. In those studies MDMA, but not methamphetamine, raises global trust[1], enhances positive responses to social feedback[2], and sharpens early neural processing of emotional faces[3]. A candidate biological substrate is identified too: MDMA strongly raises oxytocin, and that rise tracks its subjective prosocial effects[4].
For the classic psychedelics, the careful version of the claim is narrower than the popular one. A meta-analysis finds they raise emotional empathy but leave cognitive empathy unchanged[5], and the cleanest clinical demonstration, a rise in emotional empathy in depressed patients that lasted at least two weeks[6], is about feeling-with others, not reading them better. The honest framing of the evidence base is therefore: a robust acute warmth-and-trust effect (strongest for MDMA), a real but specific empathy effect for classic psychedelics, and very little controlled evidence about whether any of it changes real relationships over time.
This report summarises what Blossom’s database shows about psychedelics and the social side of life: empathy, trust, warmth, loneliness and the much-discussed idea of "connectedness". It is worth being clear at the outset what kind of page this is. It is not a condition page and not a treatment. It is about a domain of effect, how these drugs change the way people relate to others, and about a popular theory that this social effect is how they heal.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a recommendation to take psychedelics. Much of the evidence below describes acute effects in healthy volunteers under laboratory conditions, or self-reports gathered in retreats and surveys. A feeling of warmth or connection under a drug is a real experience, but it is not, by itself, evidence of lasting change in anyone’s relationships or mental health.
The solid core: MDMA and acute prosociality
The strongest, cleanest evidence in this whole topic is that MDMA acutely increases empathy, trust and social warmth. What makes it convincing is the comparison group. Researchers test MDMA against a stimulant, methamphetamine, so that ordinary stimulant sociability cannot be mistaken for something deeper. On that test MDMA stands out: it raises global trust, in one’s wider community, where methamphetamine does not[1], increases positive responses to social feedback[2], and enhances how the brain processes emotional faces[3]. A biological mechanism is identified rather than assumed: MDMA powerfully activates the oxytocin system, and the oxytocin release tracks its prosocial effects[4].
This is genuinely strong work, and it is the legitimate heart of the topic. It is also, importantly, acute. These studies measure what happens in the hours after a dose, usually in healthy volunteers. They establish, convincingly, that MDMA produces a prosocial state. They do not, on their own, establish that this state translates into durable improvement in someone’s relationships or social functioning, and it is important not to let the strength of the acute finding stand in for an outcome it does not measure.
Classic psychedelics: emotional, not cognitive, empathy
For the classic psychedelics, the careful claim is narrower than the popular one, and the difference matters. A meta-analysis found that classic psychedelics raise emotional empathy, the capacity to feel with others, but not cognitive empathy, the capacity to accurately read them[5]. The best clinical demonstration, a two-week increase in emotional empathy in depressed patients after psilocybin[6], fits the same pattern. So these drugs appear to increase warmth and emotional openness, not social skill or understanding. The everyday language of "connection" tends to blur that line, implying an improvement in relating that the data do not show.
The trouble with "connectedness"
"Connectedness" has become the field’s favourite explanation, and that is both its strength and its weakness. The strength is that it captures something real and widely reported. The weakness is that it is fuzzy, self-reported, and at risk of circularity: it is typically measured by questionnaires in the same people who also report feeling better, so "felt more connected" and "felt better" can be two descriptions of one thing rather than a cause and its effect. When a single self-reported feeling is asked to explain depression relief, addiction recovery and spiritual insight all at once, it has been stretched past the point of usefulness, a tendency captured almost literally by a proposal to rename MDMA a "connectogen"[7] encompassing connection to self, others, the body, the world and the spiritual.
The mediator studies are where this matters most. It is striking that, in trauma therapy, changes in self-compassion fully mediated MDMA’s effect on symptoms[8], and that MDMA-assisted therapy improved interpersonal self-capacities[9]. These findings are consistent with the idea that connection is the active ingredient. But they are statistical relationships among self-report measures within a trial, not proof that becoming more connected causes lasting interpersonal change. They raise the hypothesis; they do not confirm it.
What we still do not know
The biggest gap is durable, behavioural, real-world evidence. Almost everything solid is acute and self-reported. There is very little controlled work showing that psychedelics produce lasting, observer-visible improvement in real relationships or social networks. The hints that exist cut in an interesting direction: in older adults, it was the relational experience around the session, not the strength of the drug effect, that predicted later well-being[10], suggesting the human context may do much of the work. And where social effects have been tested against a placebo with proper statistics, they can evaporate: psilocybin microdosing did not reliably improve social cognition once multiple comparisons were corrected for[11].
There are also promising signals in specific groups that belong on other pages: autistic adults, for instance, self-report reduced social anxiety and more social engagement after psychedelic experiences[12], though that evidence is non-experimental and self-selected. Even ketamine shows an unexpected "entactogen-like" social-pleasure signal[13]. These are worth following, but they are early, and none of them yet closes the gap between a felt sense of connection and a measured change in a person’s social life.
Reading this honestly
So how should you read the social story? As a real domain of effect wrapped in a slightly inflated idea. The acute findings are solid, especially for MDMA: these drugs really do, in the moment, increase empathy, trust and warmth, and for MDMA that effect is specific and biologically grounded. Classic psychedelics genuinely raise emotional empathy. That much is well earned. But "connectedness" as a healing mechanism is still a hypothesis, not a result: it is measured by self-report, it is hard to separate from feeling better in general, it has been stretched to cover almost everything, and it lacks the durable, real-world, behavioural evidence that would turn it from an appealing story into an established fact. The most useful thing this literature offers an honest reader is the discipline to hold two true statements at once: that psychedelics produce a powerful and genuine social effect, and that we do not yet know whether feeling connected makes people’s actual relationships and lives lastingly better.
Acute Effect Characterisation
Acute drug effects and evidence levels observed in Interpersonal Functioning & Social Connectedness research — characterisation, not therapeutic efficacy.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| MDMA This matrix characterises the prominence of each compound’s ACUTE SOCIAL effect, not therapeutic efficacy. MDMA is the reference case: robust, replicated acute increases in empathy, trust, closeness and warmth, specific enough to separate from a stimulant comparator and linked to oxytocin. Strong as an acute social effect; mostly studied in healthy volunteers. | Large | Moderate | High |
| Psilocybin Acute social-effect characterisation, not efficacy. Raises emotional (not cognitive) empathy, including in depressed patients, and is the main locus of the "connectedness" mechanism narrative. Real but smaller and more self-report-dependent than MDMA, and the connectedness construct carries a circularity risk. | Medium | Low | Moderate |
| LSD Acute social-effect characterisation, not efficacy. Grouped with the classic psychedelics in the emotional-empathy evidence, with some social-cognition and neural-synchrony interest; microdose-level social effects are weak or null. Thinner and less specific than MDMA. | Small | Low | Moderate |
| Ayahuasca Acute social-effect characterisation, not efficacy. An ayahuasca-inspired DMT/harmine formulation acutely raised compassion for self and others, alongside naturalistic reports of gratitude and connection. Mostly uncontrolled or single-dose work, and the construct tends to drift from interpersonal to transpersonal. | Small | Low | Moderate |
| DMT Acute social-effect characterisation, not efficacy. DMT (with harmine, as an ayahuasca analogue) acutely raised compassion in healthy volunteers; the interpersonal evidence overlaps with ayahuasca and is early and small. | Small | Low | Moderate |
| Ketamine Acute social-effect characterisation, not efficacy. A surprising "entactogen-like" signal: ketamine raised social pleasure for a week in depressed patients and helping behaviour in rats. Intriguing but resting on a single reverse-translational study; not a primary prosocial agent. | Small | Very Low | Low |
MDMA and Interpersonal Functioning & Social Connectedness
MDMA is the reference case for psychedelic prosociality, and the evidence is unusually clean because researchers test it against a stimulant. That comparison matters: a sociable, talkative state could come from any stimulant, but MDMA, and not methamphetamine, specifically raises global trust[1], boosts positive responses to social feedback[2], and enhances the early neural processing of emotional faces[3]. A plausible mechanism is identified rather than assumed: MDMA is a strong activator of the oxytocin system, and the oxytocin rise tracks its prosocial and empathic effects[4].
In clinical settings, this acute warmth feeds into a mechanistic story. In trauma therapy, changes in self-compassion fully mediated MDMA’s effect on PTSD symptoms[5], and MDMA improved interpersonal self-capacities such as alexithymia and interpersonal conflict[6]. These are genuinely interesting, but they are self-report measures mediating other self-report measures in the same people, so they support, rather than prove, the idea that connection is the active ingredient. The honest position is that MDMA’s acute prosocial effect is real and well-characterised, and its role as a durable therapeutic mechanism is plausible but not yet established.
Psilocybin and Interpersonal Functioning & Social Connectedness
Psilocybin is the centre of gravity for the "connectedness" idea, the notion that these drugs work by restoring a sense of connection to self, others and the world. There is a real effect underneath it: a meta-analysis shows classic psychedelics raise emotional empathy[1], and a randomised trial found psilocybin increased emotional empathy in depressed patients for at least two weeks[2]. That is a meaningful, measurable social effect in a clinical population, not just a healthy-volunteer curiosity.
But psilocybin is also where the construct is most easily over-stretched. "Connectedness" is appealing precisely because it is broad, and breadth is also its weakness: when a single self-reported feeling is asked to explain antidepressant response, addiction recovery and spiritual insight all at once, it starts to lose explanatory bite. And the empathy effect is specifically emotional, not cognitive: psilocybin can make people feel more warmly toward others without making them any better at understanding them. The careful reading credits the real acute empathy effect and treats the grander "connection heals" narrative as an attractive hypothesis still tangled in its own self-report.
Ayahuasca and Interpersonal Functioning & Social Connectedness
Ayahuasca, and DMT more broadly, anchors the compassion-and-connection strand of this topic. A controlled study of an ayahuasca-inspired DMT and harmine formulation found acute increases in self-compassion and compassion for others[1], and the wider naturalistic literature is full of reports of gratitude, belonging and a felt connection to other people and to nature.
This strand is the clearest example of both the promise and the problem. The promise is that these are some of the warmest, most relationally themed experiences in the field, and they plainly matter to the people who have them. The problem is that the evidence is mostly uncontrolled, self-reported and gathered in settings (retreats, ceremonies) that are themselves designed to foster connection, so the drug and the context cannot be separated. The construct also tends to drift from the interpersonal (connection to specific people) to the transpersonal (connection to nature, the cosmos), which is moving and real but a long way from a measurable claim about someone’s social life.
Research Outlook
The most promising research direction is the move from acute lab effects toward genuinely relational designs. Couples-based work, in which MDMA is given to support conjoint therapy when one partner has PTSD, is the most developed example, and trials are beginning to measure dyadic outcomes such as relationship quality and even neural synchrony between people, rather than just one person’s self-report. If durable interpersonal benefit exists, this is the kind of design that could show it.
The most valuable corrective, though, comes from work that questions whether the drug is even the main ingredient. In older adults, it was relational experiences, not the intensity of the acute drug effect, that predicted later well-being[1], a hint that the human set and setting may carry much of the social benefit. And negative controls matter: psilocybin microdosing did not reliably improve social cognition once multiple comparisons were accounted for[2]. The honest outlook is a real domain of effect that is finally being studied with the relational rigour it needs, and which may turn out to be as much about people and context as about pharmacology.
Industrial Landscape
Interest in the social effects of psychedelics is broad: academic social neuroscientists and pharmacologists who run the careful acute studies, clinical developers building couples and group therapies, and a wellness and retreat industry for which "connection" is a central selling point. The construct’s popularity is itself a commercial fact: language about empathy, connection and belonging is appealing, easy to market, and harder to falsify than a symptom score, which is part of why it spreads faster than the evidence behind it. Even the academic literature shows the pull, with a proposal to rebrand MDMA as a "connectogen"[1].
For an honest broker, this is a topic to take seriously and hold to account in equal measure. The acute prosocial effects, especially MDMA’s, are real, specific and mechanistically grounded, and the relational framing captures something true about how these experiences feel and why they might help. But "connectedness" is also the field’s most over-extended idea, a warm, intuitive, self-reported construct that is easy to stretch across every outcome and hard to pin to durable, real-world change. The responsible posture credits the solid acute findings, insists on the emotional-versus-cognitive and acute-versus-durable distinctions, and treats "connection heals" as a promising hypothesis carrying more cultural weight than evidence.
Quick Indicators
Organisations
Search →National Institute on Drug Abuse (NIDA)
U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.
METIV Israel Psychotrauma Center
The METIV Israel Psychotrauma Center is a leading authority in trauma treatment and research. The center is involved in exploring MDMA-assisted therapy for PTSD, aligning with a broader mission to develop advanced treatment methods for trauma-related conditions exacerbated by conflict.
Resilient Pharmaceuticals
Resilient Pharmaceuticals (formerly Lykos Therapeutics, formerly MAPS PBC) is a US-based public benefit corporation developing MDMA-assisted therapy for PTSD. It was founded in 2014 by MAPS as a commercial spinout to carry MAPS MDMA research through late-stage trials and regulatory approval. After two Phase 3 trials and an NDA filing, FDA issued a Complete Response Letter in August 2024 and requested an additional Phase 3 trial before approval. The company subsequently restructured and rebranded, while the public Lykos web presence continues to describe the organisation as pursuing FDA approval for MDMA-assisted therapy. As of the June 2026 review, no public company announcement of a new pivotal trial start or NDA resubmission date was found. VA/DoD-backed MDMA/PTSD research is proceeding in the broader field, but it should not be treated as direct support for Resilient/Lykos NDA resubmission unless linked by company or FDA evidence.
MAPS
MAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Portland Psychotherapy
Portland Psychotherapy is a Portland, Oregon clinic, research, and training center that integrates psychedelic science into evidence-based clinical practice, conducting clinical trials of MDMA-assisted therapy for social anxiety disorder and offering psychedelic integration services. Their distinctive model funds peer-reviewed research through clinical revenue, resulting in exceptionally well-trained therapists in psychedelic-assisted care.
Columbia University
Research with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
Vancouver Island University
In response to the fallout from the COVID-19 pandemic, a research group at Vancouver Island University (VIU) has been awarded funding from the Canadian Institutes of Health Research for the exploration of psychedelic therapies for front-line workers. Led by Dr Shannon Dames, the team are currently focusing on ketamine-assisted therapy for front-line workers experiencing symptoms of PTSD and emotional distress as a result of their experiences working through the pandemic.
University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
Usona Institute
Usona Institute is a US-based 501(c)(3) non-profit medical research organisation headquartered in Madison, Wisconsin. Usona develops and supports clinical research on psilocybin and other consciousness-expanding medicines with a mission-driven access model. Its psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study, Usona launched the Phase 3 uAspire trial in 2024, a 240-participant randomised, double-blind multicentre study of 25 mg psilocybin with psychosocial support for adults with MDD. In April 2026, industry reporting said Usona confirmed it had received an FDA Commissioner National Priority Voucher for psilocybin in MDD, potentially shortening review if an NDA is filed and accepted. Usona is also exploring 5-MeO-DMT in early-stage research.
University of California San Diego
The Psychedelics and Health Research Initiative (PHRI) focuses heavily on conducting pilot studies and clinical trials while collecting diverse biometric data—including fMRI, EEG, and cognitive metrics—from study participants. This data-driven approach aims to unravel the biological and neurological underpinnings of how psychedelics facilitate healing.
Maastricht University
While Maastricht University may not have a single dedicated psychedelic research group, various researchers at the university are investigating the effects of psychedelics. Early research exploring psychedelics at Maastricht focused on the dangers of MDMA. Now, research into the effects of microdosing is being led by Dr Kim Kuypers. Other research ongoing at the university is investigating cannabis as well as novel psychoactive substances (NPS). Maastricht is collaborating on research with the Beckley Foundation as well as Silo Pharma.
People
Search →Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Aaron Klaiber
Doctoral researcher at the University of Basel
He appears as an author on multiple controlled human psychedelic studies spanning DMT, mescaline, MDMA, LSD, and psilocybin, suggesting a substantial role in contemporary psychopharmacology research.
Juliana Rocha
Doutoranda em Ciências Médicas / Saúde Mental at the Ribeirão Preto Medical School, University of São Paulo
She is a recurring coauthor on clinical psychedelic studies, especially ayahuasca trials on social anxiety, emotion recognition, personality, and social cognition, helping expand the human evidence base for psychedelic-assisted psychiatric research.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Erich Studerus
Psychologist and Scientific Director at fepsy Basel; Lecturer at FHNW
He is a recurring author on influential human psychedelic studies, especially on psilocybin, LSD, MDMA, and ayahuasca effects and predictors of response.
Anna Forsyth
Doctoral researcher / researcher at the University of Auckland
She is an author on multiple clinical studies of LSD microdosing in depression and related psychedelic psychiatry work, contributing to early human evidence on efficacy, tolerability, and mechanism.
Yvan Beaussant
Instructor in Medicine at Harvard Medical School and palliative care physician at Dana-Farber Cancer Institute
He is a leading clinical researcher in psychedelic-assisted therapy for serious illness, especially cancer-related depression, demoralization, and existential distress.
Marta Valle
PhD; researcher/lecturer in Pharmacology, Therapeutics and Toxicology at Universitat Autònoma de Barcelona and associated researcher at Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau
She is a key clinical psychopharmacology researcher on human ayahuasca studies, including neurophysiology, pharmacokinetics, and potential therapeutic effects on mindfulness and emotion regulation.
Neşe Devenot
Senior Lecturer in the University Writing Program at Johns Hopkins University
Neşe Devenot is a notable critic and scholar of psychedelic medicine whose work examines ethics, public discourse, and the social meanings of psychedelic-assisted therapy.
Christopher Davoli
Associate Professor of Psychology at Central Michigan University
He is a cognitive psychologist whose work with colleagues has helped document acute and longer-term effects of psychedelics on perception, experience, and psychological outcomes.
Heith Copes
Professor of Criminal Justice at the University of Alabama at Birmingham
Heith Copes is a criminologist whose research connects drug use, identity, and narrative meaning, including multiple collaborations on classic psychedelics, microdosing, and related social/behavioral outcomes.
Connected Evidence
The latest clinical data and verified academic findings associated with Interpersonal Functioning & Social Connectedness.